{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-398561","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2026-09-23T12:15:05+00:00","discovered_at":"2026-09-23T12:21:04.134733+00:00","generated_at":"2026-09-23T12:21:13.178463+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Corcept: President of Endocrinology Sean Maduck retires Oct 1; Justin Gunn succeeds","bullets":["Sean Maduck resigns as President, Endocrinology, effective Oct 1, 2026; no disagreement cited.","Justin Gunn appointed President, Endocrinology, assumes role Oct 1; joins Executive Team, reports to CEO.","Maduck signs consulting agreement at $57k/month through Sept 30, 2027; stock options keep vesting.","Gunn joined Corcept July 2024 as VP Sales; led sales org for Lifyorli launch; 18 yrs at Gilead.","Maduck will remain as senior commercial advisor to ensure smooth transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-398561","json":"https://secwatch.observer/filing/0001193125-26-398561.json","markdown":"https://secwatch.observer/filing/0001193125-26-398561.md","text":"https://secwatch.observer/filing/0001193125-26-398561.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526398561/0001193125-26-398561-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312526398561/d148256d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T12:21:13.178463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}